Qingdao Lingze Medical Health Technology Partnership (Limited Partnership), Xiamen Fanding Jiayin Equity Investment Partnership (Limited Partnership), Qingdao Huichuang Qihang Equity Investment Partnership (Limited Partnership), Liu Yi and Si Yali agreed to acquire 20.1% stake in Mega Genomics Health Technology (Beijing) Co., Ltd. from Meinian Onehealth Healthcare Holdings Co., Ltd. (SZSE:002044) for CNY 540 million on November 25, 2020. As per terms, Qingdao Lingze Medical Health Technology Partnership (Limited Partnership) shall acquire 15% stake for CNY 405 million, Xiamen Fanding Jiayin Equity Investment Partnership (Limited Partnership) shall acquire 2% stake for CNY 50.4 million, Qingdao Huichuang Qihang Equity Investment Partnership (Limited Partnership) shall acquire 1.3% stake for CNY 30.6 million, Liu Yi shall acquire 1% stake for CNY 27 million and Si Yali shall acquire 0.74% stake for CNY 20 million from Meinian Onehealth Healthcare Holdings Co., Ltd. Meinian Onehealth Healthcare Holdings Co., Ltd. at twenty first meeting of the seventh directorate on November 25, 2020 reviewed and passed the proposal on the sale of part of the equity interests. As on June 30, 2020, total asset and net asset of Mega Genomics Health Technology (Beijing) Co., Ltd. was CNY 405 million and CNY 333.7 million respectively. For the year ending December 31, 2020, revenue and operating profit of Mega Genomics Health Technology (Beijing) Co., Ltd. was CNY 135.5 million and CNY 49.8 million respectively. Qingdao Lingze Medical Health Technology Partnership (Limited Partnership), Xiamen Fanding Jiayin Equity Investment Partnership (Limited Partnership), Qingdao Huichuang Qihang Equity Investment Partnership (Limited Partnership), Liu Yi and Si Yali completed the acquisition of 20.1% stake in Mega Genomics Health Technology (Beijing) Co., Ltd. from Meinian Onehealth Healthcare Holdings Co., Ltd. (SZSE:002044) on December 15, 2020..